Drug Profile
AGM 290
Alternative Names: AGM-290Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator AnyGen
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in South Korea
- 14 Mar 2017 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (unspecified route)